Of the 366 patients included in the study, 178 were randomly assigned to chemoradiotherapy followed by surgery while 188 had surgery alone.
Median overall survival for the patients in the chemoradiotherapy–surgery group was 49.4 months, more than double the 24.0 month survival for the surgery group.
The research was led by Dr. Ate van der Gaast at the department of medical onocology at Erasmus University Hospital in Rotterdam, Netherlands.
Related Articles on Cancer:
NB’s Good Samaritan Hospital Wins Colorectal Cancer Screening and Awareness Challenge
Cannabinoid Therapy Proves Effective as Cancer Pain Treatment
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
